Several large‐scale clinical trials and clinical experiences have established the remarkable benefits of immune checkpoint inhibitors (ICI); anti‐programmed death‐1 (PD‐1) and PD‐ligand 1 (PD‐L1) in the treatment of patients with non‐small cell lung cancer (NSCLC).1, 2, 3, 4, 5 Thus, cancer immunotherapy continues to receive attention in research. This evidence concerns the gene CD274 and lung cancer.